vitamin d

Ergocalciferol (Vitamin D2 (Calciferol)) is a derivative of ergosterol formed by ultraviolet rays breaking of the C9-C10 bond with a strong inhibitory effect against bladder tumor promotion by sodium saccharin, and it induces cell differentiation in leukemia cells. Vitamin D2 is an inhibitor of DNA Polymerase.

Vitamin D3 (cholecalciferol) is a naturally occurring form of vitamin D; once metabolically activated, it can induce cellular differentiation and cancer cell proliferation. Vitamin D3 can be used to establish kidney stone models and is also an important research target in the fields of immunology and oncology.

Calcitriol (1,25-Dihydroxyvitamin D3) is a metabolite of vitamin D and a vitamin D receptor (VDR) agonist (IC50=0.4 nM). Calcitriol increases intestinal absorption of calcium and phosphorus, and increases bone resorption with parathyroid hormone.

Calcipotriol (MC 903) is a synthetic vitamin D3 analogue with high affinity for the vitamin D receptor.

Maxacalcitol (22-Oxacalcitriol) is a ligand of VDR-like receptors and a non-serum calcium vitamin D3 analogue. Maxacalcitol inhibits parathyroid hormone (PTH) mRNA expression in vitro and in vivo.

Tributyrin (Glyceryl tributyrate), a neutral short-chain fatty acid triglyceride, is a stable and rapidly absorbed prodrug of Butyric Acid. It diffuses through biological membranes and is metabolized by intracellular lipases, releasing effective butyrate directly into cells in vivo, exhibiting potent proapoptotic, antiproliferative, and differentiation-inducing effects.

Inecalcitol is a unique vitamin D3 analog that induces apoptosis and has anticancer activity. It is an orally active vitamin D receptor agonist with a Kd of 0.53 nM.

Doxercalciferol (TSA 840) is a synthetic vitamin D2 analog, suppressing parathyroid synthesis and secretion, used to treat secondary hyperparathyroidism and metabolic bone disease.

Alfacalcidol (Etalpha) (1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3) is a non-selective VDR activator medication.

Calcifediol (U 32070E) is a naturally occurring product that is metabolized in the liver from vitamin D3, a VDR ligand. Calcifediol is indicated for use as a vitamin supplement for all patients with vitamin D deficiency.

Calcifediol monohydrate (25-hydroxy Vitamin D3 monohydrate), the primary circulating metabolite of Vitamin D3, serves as a potent VDR inhibitor.

Paricalcitol is a selective vitamin D receptor agonist and a vitamin D analog. Paricalcitol potently inhibits the synthesis and secretion of parathyroid hormone (PTH) and is commonly used in studies of secondary hyperparathyroidism in patients with chronic kidney disease.

Calcipotriol monohydrate is an analog of Vitamin D3 with a high affinity for the vitamin D receptor. Calcipotriol monohydrate can be used for studies about psoriasis.

3-epi-25-hydroxy Vitamin D3 is the C-3 epimer of 25-hydroxy vitamin D3. Dietary administration of 3-epi-25-hydroxy vitamin D3 (0.5 and 1 IU/g) decreases levels of serum parathyroid hormone (PTH) in male, but not female, weanling rats.

1α-Hydroxy-3-epi-vitamin D3, a natural metabolite derived from 1alpha,25-dihydroxyvitamin D3, effectively suppresses parathyroid hormone (PTH) secretion [1].

Vitamin D3 octanoate, an ester derived from vitamin D3, is commonly known as cholecalciferol. Cholecalciferol is a naturally occurring form of vitamin D with notable properties such as inducing cell differentiation and impeding cancer cell proliferation.

Human vitamin D-binding protein (hDBP) is an abundant, multifunctional, and highly polymorphic serum glycoprotein synthesized by the liver1.

(R)-Vitamin D2 is an isomer of Vitamin D2, and it can serve as a control compound in experiments. Vitamin D2 (Ergocalciferol) is sourced from food or dietary supplements and is used as a supplement for Vitamin D.

3-epi-Vitamin D3 (Epicholecalciferol), an analogue of Vitamin D3, serves as a Hedgehog pathway inhibitor, exhibiting potency with an IC50 value of 39.2 μM in U87MG cells.

Pre-vitamin D3 decanoate, a derivative of vitamin D3, can be transformed into the active form of vitamin D in the body. Initially, it is converted to 25-hydroxyvitamin D3 in the liver and then to 1,25-dihydroxyvitamin D3 in the kidneys. During preparation, vitamin D3 might react with triglycerides in the formulation, forming ester compounds that impact the stability and bioavailability of vitamin D3. This compound is utilized in the study of diseases related to vitamin D, including osteoporosis, autoimmune diseases, and certain cancers.

25-Hydroxy vitamin D2-D3 is a deuterated compound of 25-Hydroxy vitamin D2 (TMSM-0001).

25-Hydroxy vitamin D3-D3 is a deuterated compound of 25-Hydroxy vitamin D3 (TMSM-3156).

Vitamin D3-D3 is a deuterated compound of Vitamin D3.

1α,25-Dihydroxy-3-epi-vitamin D2-d9 is the deuterium-labeled version of 1α,25-Dihydroxy-3-epi-vitamin D2.